Across TCGA pan-cancer cohorts, VASH1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated VASH1 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher VASH1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated VASH1 expression acts as an unfavorable survival marker.
SKCM, SARC, and PRAD are the cancer types where VASH1 Mutation most reproducibly stratifies survival.